Quarterly activities and cashflow report
Filed with ASX ·
6ix is reading this filing.
Earlier from CLEO Diagnostics
- CLEO Screening Test Meets Rigorous Performance Targets
- CLEO Commences Analytical Validation Ahead of FDA Submission
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Ovarian Cancer Screening Test Development
- CLIA Certified Lab selected - Pivotal US Clinical Validation
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics